Rational Design of Non-Toxic Multidrug Combinations Demonstrates Durable and Hypoxia-Enhanced Efficacy Against Renal Cell Carcinoma
Authors:
- Valentin MievilleVMValentin Mieville
- Jakub GubalaJGJakub Gubala
- Mathis FiaultMFMathis Fiault
- Marie OtaMOMarie Ota
- Seungsu HanSHSeungsu Han
- Muriel UrwylerMUMuriel Urwyler
- Daniel BenamranDBDaniel Benamran
- Jean-Christophe TilleJTJean-Christophe Tille
- Massimo ValerioMVMassimo Valerio
- Patrycja Nowak-SliwinskaPNPatrycja Nowak-Sliwinska
Open Access
- 27 September 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (10) , 1269
Abstract
Background/Objectives: Despite recent therapeutic advances, the clinical management of renal cell carcinoma (RCC) remains suboptimal. Current treatments are hindered by limited efficacy, the emergence of acquired drug resistance, suboptimal tolerability, and a lack of tumor-specific targeting. While development of novel agents remains an important avenue, it is often constrained by high costs, long development time, and low success rates. As an alternative approach, drug combinations of approved agents offer a promising strategy. Methods: Using our proprietary drug combination methodology, we identified multidrug combinations in RCC cells representing the clear cell (786O) and sarcomatoid chromophobe (UOK276) histological subtypes of RCC. Results: From an initial panel of 10 drugs, either approved or undergoing clinical trial, the optimized drug combinations (ODCs) contained crizotinib, telaglenastat, U-104, and vismodegib at clinical and subtherapeutic doses. The ODCs were non-toxic in advanced hepatic, renal, and cardiac cellular models. Importantly, their anti-tumor activity, already notable in normoxic (21% O2) conditions (approx. 50%) was markedly enhanced in tumor-relevant hypoxia (1.5% O2), reaching up to 77% in 2D and 62% in 3D spheroid 786O models. Moreover, chronic exposure of 786O and UOK276 cells led to durable responses, suggesting a prolonged effect in responders. Conclusions: Our findings demonstrate the potential of optimized, non-toxic drug combinations as a highly selective and effective strategy for accelerating the development of precision RCC treatment.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_197878)
This publication has 73 references indexed in Scilit:
- Costs of Drug Development and Research and Development Intensity in the US, 2000-2018JAMA Network Open, 2024
- The Advent of Molecular Targeted Therapies Against Cancer. Toward Multi‐Targeting Drugs Through Materials Engineering: A Possible Future ScenarioSmall Science, 2024
- Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2024
- Advanced in vitro models for renal cell carcinoma therapy designBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023
- Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancerCellular and Molecular Life Sciences, 2023
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- Optimized low‐dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatmentMolecular Oncology, 2020
- Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx RenalCell, 2018
- Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276)Genes, Chromosomes and Cancer, 2017
- Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairmentCancer Chemotherapy and Pharmacology, 2017